Controversies and misconceptions in malaria chemoprophylaxis for travelers

JAMA

Volumn 297, Issue 20, 2007, Pages 2251-2263

  Chen, Lin H ^a,b   Wilson, Mary E ^a,b,c   Schlagenhauf, Patricia ^d  

^a MOUNT AUBURN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; CLINDAMYCIN; DIETHYLTOLUAMIDE; DIHYDROFOLATE REDUCTASE INHIBITOR; DOXYCYCLINE; HALOFANTRINE; HYDROXYCHLOROQUINE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; QUININE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; ANTIMALARIAL AGENT;

ABSENCE OF SIDE EFFECTS; ANGER; ANOPHELES; AVIATION; BIPOLAR DISORDER; BODY EQUILIBRIUM; CARDIOVASCULAR FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONVULSION; DEPRESSION; DISABILITY; DIVING; DIZZINESS; DREAM; DRIVING ABILITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EMERGENCY TREATMENT; ENDEMIC DISEASE; FATIGUE; GEOGRAPHIC DISTRIBUTION; HEARING; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSOMNIA; LICENSING; MALARIA; MALARIA CONTROL; MEDLINE; MENTAL CONCENTRATION; MENTAL DISEASE; MOOD DISORDER; MOTOR COORDINATION; NAUSEA; NEUROLOGIC DISEASE; PANIC; PARASITE VECTOR; PATIENT COMPLIANCE; PHARMACOGENETICS; PLASMODIUM VIVAX; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; PSYCHOSIS; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; TRAVEL; TREATMENT OUTCOME; VISUAL HALLUCINATION; ATTITUDE TO HEALTH; COMPARATIVE STUDY; CONSENSUS; INTERNATIONAL COOPERATION;

ANTIMALARIALS; CONSENSUS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNATIONALITY; MALARIA; MEFLOQUINE; PRACTICE GUIDELINES; PRIMAQUINE; TRAVEL;

EID: 34249713794     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.20.2251     Document Type: Review

References (114)

1. Hughes C, Tucker R, Bannister B, Bradley DJ; Health Protection Agency Advisory Committee on Malaria Prevention for UK Travellers (ACMP). Malaria prophylaxis for long-term travelers. Commun Dis Public Health. 2003;6:200-208.
2. Committee to Advise on Tropical Medicine and Travel (CATMAT). 2004 Canadian recommendations for the prevention and treatment of malaria among international travellers. Can Commune Dis Rep. 2004;30 (suppl 1):1-62.
3. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA. 2006;296:2234-2244.
4. Bradley DJ, Bannister B; Health Protection Agency Advisory Committee on Malaria Prevention for UK Travellers. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Comm Dis Public Health. 2003;6:180-199.
5. Malaria. In: Health Information for International Travel 2005-2006. Atlanta, Ga: US Dept of Health and Human Services, Public Health Service; 2005.
6. Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines of the Infectious Disease Society of America. http://www.journals. uchicago.edu/CID/journal/issues/v43n12/40908/40908.web.pdf. Accessed November 20, 2006.
7. Chiodini P, Hill D, Lalloo D, et al. Guidelines for malaria prevention in travellers. London, England: Health Protection Agency; January 2007. http://www.hpa.org.uk/infections/topics_az/malaria/ACMP.htm. Accessed December 20, 2006).
8. Institut de Veille Sanitaire. Sante des voyageurs et recommendations sanitaires 2006 [editorial]. Bull Epidemiologique Hebdomadaire. 2006;23-24:153-159. http://www.invs.sante.fr/beh/2006/23_24/beh_23_24_2006.pdf. Accessed November 19, 2006.
9. Bialek R, Burchard G-D, Jelinek T, et al. Empfehlungen Malariavorbeugung Januar 2007. Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG). http://www.dtg.org/uploads/media/ DTG_Malariaempfehlungen_2007_01.pdf. Accessed January 8, 2007.
10. Hatz C, Beck B, Blum J, et al. Update zum Malariaschutz für Kurzzeitaufenthalter. Bull Bundesamt Gesundheit. 2007;11:212-214.
11. Study Group for Malaria Prevention and Treatment. Malaria Prevention Guideline for Japanese Travelers - Malaria Prevention Specialist Meeting 2005 [in Japanese]. Tokyo, Japan: Free Press; 2005;1-43.http://jsp.tm. nagasaki-u.ac.jp/modules/tinyd3/index.php?id=2. Accessed November 2, 2006.
12. Antibiotic Expert Group. Malaria. In: Therapeutic Guidelines Antibiotic. Version 13. North Melbourne, Australia: Therapeutic Guidelines Ltd; 2006.
13. Malaria. In: International Travel and Health. Geneva, Switzerland: World Health Organization; 2005: 132-151. http://whqlibdoc.who.int/ publications/2005/9241580364_chap7.pdf. Accessed November 15, 2006.
14. Country list: vaccination requirements and malaria situation. In: International Travel and Health. Geneva, Switzerland: World Health Organization; 2005: 154-181. http://whqlibdoc.who.int/publications/2005/ 9241580364_country_list.pdf. Accessed November 15, 2006.
15. Centers for Disease Control and Prevention. Yellow Fever Vaccine Requirements and Information on Malaria Risk and Prophylaxis, by Country: Health Information for International Travel 2007-2008. Atlanta, Ga: US Dept of Health and Human Services, Public Health Service. In press.
16. Development of recommendations for the protection of short-stay travelers to malaria endemic areas: memorandum from two WHO meetings. Bull World Health Organ. 1988;66:177-196.
17. Schlagenhauf P, Steffen R, Tschopp A, et al. Behavioural aspects of travelers in their use of malaria presumptive treatment. Bull World Health Organ. 1995;73:215-221.
18. Nothdurft HD, Jelinek T, Pechel SM, et al. Standby treatment of suspected malaria in travelers. Trop Med Parasitol. 1995;46:161-163.
19. Causer LM, Filler S, Wilson M, Papagiotas S, Newman RD. Evaluation of reported malaria chemoprophylactic failure among travelers in a US University Exchange Program, 2002. Clin Infect Dis. 2004;39:1583-1588.
20. Reyburn H, Mbatia R, Drakely C, Carneiro I, et al. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ. 2004;329:1212.
21. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2:e100.
22. Newton PN, McGready R, Fernandez F, et al. Manslaughter by fake artesunate in Asia - will Africa be next? PLoS Med. 2006;3:e197.
23. Newton PN, Green MD, Fernandez FM, Day NPJ, White NJ. Counterfeit anti-infective drugs. Lancet Infect Dis. 2006;6:602-613.
24. Delaunay P, Cua E, Lucas P, Marty P. Homoeopathy may not be effective in preventing malaria. BMJ. 2000;321:1288.
25. Carlsson T, Bergqvist L, Hellgren U. Homeopathic resistant malaria. J Travel Med. 1996;3:62.
26. Sudakin DL, Trevathan WR. DEET: a review and update of safety and risk in the general population. J Toxicol Clin Toxicol. 2003;41:831-839.
27. Centers for Disease Control and Prevention. Health Information for International Travel. Atlanta, Ga: US Dept of Health and Human Services, Public Health Service; 2005. http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp? section=recs&obj=bugs.htm&cssNav=browseoyb. Accessed October 5, 2005.
28. American Academy of Pediatrics. Follow safety precautions when using DEET on children. www.aap.org/family/wnv-jun03.htm. Accessed July 14, 2006.
29. Frances SP, Van Dung N, Beebe NW, Debboun M. Field evaluation of repellent formulations against daytime and nighttime biting mosquitoes in a tropical rainforest in northern Australia. J Med Entomol. 2002;39:541-544.
30. Badolo A, Ilboudo-Sanogo E, Ouedraogo AP, Costantini C. Evaluation of the sensitivity of Aedes aegypti and Anopheles gambiae complex mosquitoes to two insect repellents: DEET and KBR 3023. Trop Med Int Health. 2004;9:330-334.
31. Frances SP, Waterson DG, Beebe NW, Cooper RD. Field evaluation of repellent formulations containing deet and picaridin against mosquitoes in Northern Territory, Australia. J Med Entomol. 2004;41:414-417.
32. Costantini C, Badolo A, Ilboudo-Sanogo E. Field evaluation of the efficacy and persistence of insect repellents DEET, IR3535, and KBR 3023 against Anopheles gambiae complex and other Afrotropical vector mosquitoes. Trans R Soc Trop Med Hyg. 2004;98:644-652.
33. Wells TS, Smith TC, Smith B, et al. Mefloquine use and hospitalizations among US service members, 2002-2004. Am J Trop Med Hyg. 2006;74:744-749.
34. Kitchener SJ, Nasveld PE, Gregory RM, Edstein MD. Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med J Aust. 2005;182:168-171.
35. van Riemsdijk MM, Sturkenboom MC, Pepplinkhuizen L, Stricker BH. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. J Clin Psychiatry. 2005;66:199-204.
36. Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis, or panic attacks with prophylactic antimalarials. Drug Saf. 2004;27:203-213.
37. Schlagenhauf P, Tschopp A, Johnson R, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003;327:1078-1081.
38. van Riemsdijk MM, Ditters JM, Sturkenboom MC, et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol. 2002;58:441-445.
39. van Riemsdijk MM, Sturkenboom MC, Ditters JM, et al. Atovaquone plus chlorguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther. 2002;72:294-301.
40. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophyhlaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis. 2001;33:1015-1021.
41. Croft AM, Garner P. Mefloquine for preventing malaria in non-immune adult travellers [update of: Cochrane Database Syst Rev. 2000;(3):CD000138]. Cochrane Database Syst Rev. 2000;(4):CD000138.
42. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg. 2001;65:189-192.
43. Lobel HO, Baker MA, Gras FA, et al. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med. 2001;8:167-172.
44. Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2,500 long term young travelers to the tropics. J Travel Med. 2000;7:5-9.
45. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:963-972.
46. Hoebe C, de Munter J, Thijs C. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis. Eur J Clin Pharmacol. 1997;52:269-275.
47. Phillips MA, Kass RB. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med. 1996;3:40-45.
48. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparasion of adverse events associated with the use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ. 1996;313:525-528.
49. Croft AM, World MJ. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet. 1996;347:326.
50. Corbett EL, Doherty JP, Behrens RH. Adverse events associated with mefloquine: study in returned travellers confirms authors' findings. BMJ. 1996;313:1552.
51. Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health. 1996;1:485-494.
52. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol. 1993;44:257-265.
53. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet. 1993;341:1299-1303.
54. Lobel HO, Miani M, Eng T, et al. Long-term malaria prophylaxis with weekly mefloquine. Lancet. 1993;341:848-851.
55. Bem JL, Kerr L, Stürchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg. 1992;95:167-179.
56. Weinke T, Trautman M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg. 1991;45:86-91.
57. Sturchler D, Handschin J, Kaiser D, et al. Neuropsychiatric side effects of mefloquine. N Engl J Med. 1990;322:1752-1753.
58. Mannino S, Hoskins R, Biondi L, et al. A study on the safety of mefloquine in prophylaxis based on intensive monitoring. In: Proceedings of the 2nd International Conference on the Prevention of Infection;May 4-5, (1992; Nice, France; Abstract C11.
59. MacPherson D, Gamble K, Tessier D, et al. Mefloquine tolerance- randomised, double-blinded, placebo-controlled study using a loading dose of mefloquine in pre-exposed travellers. In: Program and Abstracts of the Fifth International Conference on Travel Medicine; March 24-27, 1997; Geneva, Switzerland. Abstract 220.
60. Ollivier L, Tifratene K, Josse R, Keundjian A, Boutin JP. The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study. Ann Trop Med Parasitol. 2004;98:639-641.
61. Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf. 1995;12:370-383.
62. Wittes RC, Sagmur R. Adverse reactions to mefloquine associated with ethanol ingestion. CMAJ. 1995;152:515-517.
63. Vuurman EF, Muntjewerff ND, Uiterwijk MM,et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol. 1996;50:475-482.
64. Aarnoudse AL, van Schaik RH, Dieleman J, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther. 2006;80:367-374.
65. Schlagenhauf P, Lobel HO, Steffen R, et al. Tolerability of mefloquine in Swissair trainee pilots. Am J Trop Med Hyg. 1997;56:235-240.
66. Hessen-Soederman AC, Bergenius J, Berggren I, et al. Mefloquine prophylaxis, and hearing, postural control, and vestibular functions. J Travel Med. 1995;2:66-69.
67. Davis TME, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo controlled trial. Br J Clin Pharmacol. 1996;42:415-421.
68. Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. Infect Dis Clin North Am. 2005;19:185-210.
69. Schlagenhauf P, Beallor C, Kain KC. Malaria chemoprophylaxis. In: Keystone JS, Kozarsky PE, Freedman DO, Nothdurft HD, Connor BA, eds. Travel Medicine. Edinburgh, Scotland: Mosby; 2004:137-156.
70. Baird JK, Basri H, Purnomo , et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1991;44:547-552.
71. Schwartz IK, Lackritz EM, Patchen MS. Chloroquine-resistant Plasmodium vivax from Indonesia. N Engl J Med. 1991;324:927.
72. Jiménez BC, Navarro M, Huerga H, Lopez-Romain E, Mendoza A, Lopez-Velez R. Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis. J Travel Med. 2006;13:373-375.
73. Povinelli L, Fox BC, Parise ME, Monson TA, Morrisey JM, Vaidya AB. Plasmodium vivax malaria in spite of atovaquone/proguanil (Malarone) prophylaxis. J Travel Med. 2003;10:353-355.
74. Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007;9:39-46.
75. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64(1-2 suppl):97-106.
76. Sina B. Focus on Plasmodium vivax. Trends Parasitol. 2002;18:287-289.
77. Eliades MJ, Shah S, Nguyen-Dinh P, et al. Malaria surveillance - United States, 2003. MMWR Surveill Summ. 2005;54:25-38.
78. Skarbinski J, James EM, Causer LM, et al. Malaria surveillance - United States, 2004. MMWR Surveill Summ. 2006;55:23-37.
79. Baas MC, Eststeyn JCFM, van Gool T. Patterns of imported malaria at the Academic Medical Center, Amsterdam, the Netherlands. J Travel Med. 2006;13:2-7.
80. Gentilini M, Trape JF, Danis M, et al. Imported malaria in a hospital in Paris. Trans R Soc Trop Med Hyg. 1981;75:455-460.
81. Jelinek T, Nothdurft HD, Loscher T. Malaria in nonimmune travelers: a synopsis of history, symptoms, and treatment in 160 patients. J Travel Med. 1994;1:199-202.
82. Muhlberger N, Jelinek T, Gascon J, et al. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J. 2004;3:5.
83. Kain KC, Harrington MA, Tennyson S, Keystone JS. Imported malaria: prospective analysis of problems in diagnosis and management. Clin Infect Dis. 1998;27:142-149.
84. Svenson JE, MacLean JD, Gyorkos TW, Keystone J. Imported malaria: clinical presentation and examination of symptomatic travelers. Arch Intern Med. 1995;155:861-868.
85. Boreham RE, Relf WA. Imported malaria in Australia. Med J Aust. 1991;155:754-757.
86. Elliott JH, O'Brien D, Leder K, et al. Imported Plasmodium vivax malaria: demographic and clinical features in nonimmune travelers. J Travel Med. 2004;11:213-217.
87. Robinson P, Jenney AW, Tachado M, et al. Imported malaria treated in Melbourne, Australia: epidemiology and clinical features in 246 patients. J Travel Med. 2001;8:76-81.
88. Bottieau E, Clerinx J, van den Enden E, et al. Imported non-plasmodium falciparum malaria: a five-year prospective study in a European referral center. Am J Trop Med Hyg. 2006;75:133-138.
89. Hemmer CJ, Holst FGE, Kern P, Chiwakata CB, Dietrich M, Reisinger EC. Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria. Trop Med Int Health. 2006;11:817-823.
90. Karunaweera ND, Carter R, Gamage P, Mendis KN. Dynamics of fever and serum TNF levels are closely associated during clinical symptoms in P vivax malaria. Proc Natl Acad Sci U S A. 1992;89:3200-3203.
91. Anstey NM, Handojo T, Pain MC, et al. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis. 2007;195:589-596.
92. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A. Plasmodium vivax malaria. Emerg Infect Dis. 2005;11:132-134.
93. Carlini ME, White AC Jr, Atmar RL. Vivax malaria complicated by adult distress syndrome. Clin Infect Dis. 1999;28:1182-1183.
94. Rodríguez-Morales A, Benitez JA, Franco-Paredes C. Acute respiratory distress syndrome in Plasmodium vivax malaria in traveler returning from Venezuela [letter]. J Travel Med. 2006;13:325-326.
95. Beg MA, Khan R, Baig SM, et al. Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg. 2002;67:230-232.
96. Lawn SD, Krishna S, Jarvis JN, et al. Case reports: pernicious complications of benign tertian malaria. Trans R Soc Trop Med Hyg. 2003;97:551-553.
97. Saleri N, Gulletta M, Matteelli A, et al. Acute respiratory distress syndrome in Plasmodium vivax malaria in traveler returning from Venezuela. J Travel Med. 2006;13:112-113.
98. Torres JR, Perez H, Postigo MM, Silva JR. Acute non-cardiogenic lung injury in benign tertian malaria. Lancet. 1997;350:31-32.
99. Gockel HR, Heidmann J, Lorenz D, Gockel I. Spontaneous splenic rupture in tertian malaria. Infection. 2006;34:43-45.
100. Oh M-D, Shin H, Shin D, et al. Clinical features of vivax malaria. Am J Trop Med Hyg. 2001;65:143-146.
101. Baird JK. A rare glimpse at the efficacy of primaquine. Am J Trop Med Hyg. 2007;76:201-202.
102. Goller JL, Jolley D, Ringwald P, Biggs B-A. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg. 2007;76:203-207.
103. Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria-implications for chemoprophylaxis in travelers. N Engl J Med. 2003;349:1510-1516.
104. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg. 2006;75:402-415.
105. Fryauff DJ, Baird JK, Basri H, et al. Randomized, placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria in Indonesia. Lancet. 1995;346:1190-1193.
106. Baird JK, Lacy MD, Basri H, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis. 2001;33:1990-1997.
107. Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis. 2003; 37:1659-1667.
108. Soto J, Toledo J, Rodriquez M, et al. Primaquine prophylaxis against malaria in non immune Colombian soldiers: efficacy and toxicity: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129:241-244.
109. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336-1345.
110. Alving AS, Arnold J, Hockwald RS, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955;46:301-306.
111. Barrett JP, Behrens RH. Prophylaxis failure against vivax malaria in Guyana, South America. J Travel Med. 1996;3:60-61.
112. Smoak BL, DeFraites RF, Magill AJ, Kain KC, Wellde BT. Plasmodium vivax infections in US Army troops: failure of primaquine to prevent relapses in studies from Somalia. Am J Trop Med Hyg. 1997;56:231-234.
113. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol. 2006;22:353-358.
114. Schlagenhauf-Lawlor P, Funk-Baumann M. PDQ Traveler's Malaria. Hamilton, Ontario: BC Decker; 2005.